Distinct Clinicogenomic Contexts of BRAF ‐Altered Gliomas and Glioneuronal Tumors: A Nationwide Real‐World Study
Open Access
- 18 October 2026
- journal article
- Published by Wiley in Cancer Science
Abstract
BRAF alterations occur across diverse gliomas and glioneuronal tumors, but their alteration‐specific clinicogenomic contexts in real‐world cancer genomic profiling cohorts remain incompletely characterized. We analyzed BRAF ‐altered brain tumors registered in the Japanese Center for Cancer Genomics and Advanced Therapeutics database from June 2019 to March 2026. Operational diagnostic harmonization was performed using available clinicopathological and genomic information. Grade‐stratified analyses focused on BRAF p.V600E‐positive gliomas and glioneuronal tumors. Among 413 BRAF ‐altered brain tumors, 344 were classified as gliomas and glioneuronal tumors after harmonization. Within this cohort, the major alteration contexts included BRAF p.V600E‐positive tumors ( n = 166), KIAA1549 :: BRAF fusion‐positive tumors ( n = 60), amplification‐only tumors ( n = 15), and tumors with other BRAF alterations ( n = 109), with overlap in a subset. KIAA1549 :: BRAF fusion‐positive tumors were mainly associated with low‐grade glioma contexts, particularly pilocytic astrocytoma. Amplification‐only tumors showed marked enrichment of MET alterations, all representing MET amplification, together with frequent EGFR and TP53 co‐alterations, supporting a receptor tyrosine kinase‐amplified, copy‐number‐rich context. Among 118 grade‐evaluable BRAF p.V600E‐positive gliomas and glioneuronal tumors, CDKN2A/B homozygous deletion and TP53 / ATRX alterations were enriched in higher‐grade groups, and high‐grade tumors showed increased tumor mutational burden, although hypermutator phenotypes were rare. BRAF alteration classes define distinct clinicogenomic contexts in gliomas and glioneuronal tumors. These findings highlight both the opportunities and methodological challenges of nationwide real‐world cancer genomic profiling datasets in central nervous system tumor research.Keywords
This publication has 12 references indexed in Scilit:
- Efficacy of tepotinib in patients with high-grade glioma with MET alterations: A case seriesNeuro-Oncology Practice, 2025
- EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selectionNeuro-Oncology, 2023
- Novel RAF Fusions in Pediatric Low-Grade Gliomas Demonstrate MAPK Pathway ActivationJournal of Neuropathology & Experimental Neurology, 2021
- Targetable BRAF and RAF1 Alterations in Advanced Pediatric CancersThe Oncologist, 2020
- Biology and grading of pleomorphic xanthoastrocytoma—what have we learned about it?Brain Pathology, 2020
- cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and gradingBrain Pathology, 2020
- Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade GliomasCancer Cell, 2020
- The genetic landscape of anaplastic pleomorphic xanthoastrocytomaBrain Pathology, 2018
- Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysisBrain Pathology, 2017
- Pediatric low-grade gliomas: next biologically driven stepsNeuro-Oncology, 2017